Newly Reported Drugs: The following drugs were reported to NFLIS-Drug for the first time between April 1, 2020, and June 30, 2020, and were submitted to a NFLIS participating laboratory on or after April 1, 2019.

**Emerging Drug Trends**

The charts below depict the number of reports (y axis) for selected emerging drugs that were submitted to a NFLIS participating laboratory from November 2018 through March 2020 and received by NFLIS-Drug by June 30, 2020.

**Data Disclaimer:** Substances identified by Federal, State, and local laboratories are included in the raw counts of drug reports received by NFLIS-Drug. Raw counts have not undergone any adjustments to account for laboratory nonresponse. Data for this publication were exported from the NFLIS-Drug database in July 2020 and include drug reports received by NFLIS-Drug through the end of June 2020. Because of the time it takes for a laboratory to analyze seized material and transfer the data to the NFLIS database, the data in this publication—unlike those reported in an Annual or Midyear Report—are not comprehensive and do not reflect total counts of drugs analyzed over the period. More information on NFLIS data limitations can be found in the NFLIS Questions and Answers guide: [https://www.nflis.deadiversion.usdoj.gov/DesktopModules/ReportDownloads/Reports/2k17NFLISQA.pdf](https://www.nflis.deadiversion.usdoj.gov/DesktopModules/ReportDownloads/Reports/2k17NFLISQA.pdf). NFLIS reports are available at [https://www.nflis.deadiversion.usdoj.gov/Reports.aspx](https://www.nflis.deadiversion.usdoj.gov/Reports.aspx). Questions and comments: DEANFLIS@rti.org